Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
作者信息
Tu S Sean, Kesselheim Aaron S, Wetherbee Kathrine, Feldman William B
机构信息
West Virginia University College of Law, Morgantown.
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
JAMA. 2023 Aug 1;330(5):469-470. doi: 10.1001/jama.2023.11525.
Abstract
摘要
相似文献
1
Changes in the Number of Continuation Patents on Drugs Approved by the FDA.美国食品药品监督管理局（FDA）批准的药品延续专利数量的变化。
JAMA. 2023 Aug 1;330(5):469-470. doi: 10.1001/jama.2023.11525.
2
Strategies That Delay Market Entry of Generic Drugs.延缓仿制药上市的策略。
JAMA Intern Med. 2017 Nov 1;177(11):1665-1669. doi: 10.1001/jamainternmed.2017.4650.
3
Determinants of Market Exclusivity for Prescription Drugs in the United States.美国处方药市场独占的决定因素。
JAMA Intern Med. 2017 Nov 1;177(11):1658-1664. doi: 10.1001/jamainternmed.2017.4329.
4
Comparing Onset of Biosimilar Versus Generic Competition in the United States.比较美国生物类似药与仿制药竞争的起点。
Clin Pharmacol Ther. 2020 Dec;108(6):1308-1314. doi: 10.1002/cpt.1981. Epub 2020 Aug 17.
5
Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.面临专利到期的品牌药产品线延伸及定价策略
J Manag Care Pharm. 2005 Nov-Dec;11(9):746-54. doi: 10.18553/jmcp.2005.11.9.746.
6
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.GLP-1 受体激动剂的专利和监管专有权。
JAMA. 2023 Aug 15;330(7):650-657. doi: 10.1001/jama.2023.13872.
7
Using a drug-safety tool to prevent competition.使用药物安全工具来防止竞争。
N Engl J Med. 2014 Apr 17;370(16):1476-8. doi: 10.1056/NEJMp1400488.
8
Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.专利组合保护十大畅销处方药。
JAMA Intern Med. 2024 Jul 1;184(7):810-817. doi: 10.1001/jamainternmed.2024.0836.
9
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?药品命名改革的理由：通用名药品上市后品牌名商标保护是否应到期？
PLoS Med. 2016 Feb 9;13(2):e1001955. doi: 10.1371/journal.pmed.1001955. eCollection 2016 Feb.
10
Characteristics Of Key Patents Covering Recent FDA-Approved Drugs.最近获得美国 FDA 批准的药物的关键专利的特点。
Health Aff (Millwood). 2022 Aug;41(8):1117-1124. doi: 10.1377/hlthaff.2022.00002.
引用本文的文献
1
Revenue, Patents, and New Generic Competition for Prescription Drugs in the USA.美国处方药的收入、专利与新的仿制药竞争
J Gen Intern Med. 2025 Jul 14. doi: 10.1007/s11606-025-09717-x.
2
Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs.美国专利局关于重复专利的相互矛盾的裁决危及仿制药和生物类似药。
Pharm Pat Anal. 2024;13(4-6):95-103. doi: 10.1080/20468954.2025.2459582. Epub 2025 Feb 8.
3
Use of Track One Prioritized Examination for Pharmaceutical Patents.对药品专利使用一级优先审查
JAMA Health Forum. 2024 Jul 5;5(7):e241886. doi: 10.1001/jamahealthforum.2024.1886.
4
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.美国食品和药物管理局批准的胰岛素产品的专利和监管专有权：1986-2019 年的纵向数据库研究。
PLoS Med. 2023 Nov 16;20(11):e1004309. doi: 10.1371/journal.pmed.1004309. eCollection 2023 Nov.
本文引用的文献
1
A "Method of Use" to Prevent Generic and Biosimilar Market Entry.一种防止仿制药和生物类似药进入市场的“使用方法”。
N Engl J Med. 2023 Feb 9;388(6):483-485. doi: 10.1056/NEJMp2216020. Epub 2023 Jan 25.
Zotero 插件